Markowska J, Lacki J K, Jaroszewski J, Wiktorowicz K
Dept of Oncology, University School of Medicine Poznan, Poland.
Eur J Gynaecol Oncol. 1995;16(1):54-8.
Twenty-seven ovarian cancer patients were observed for twenty-four months. The patients were grouped as follows: Group I-with complete (CR) or partial remission (PR), Group II-with stable disease (SD), Group III-with progression (PD) of the disease. In all patients, T lymphocyte phenotypes were estimated in peritoneal fluid (PF) and in peripheral blood (PB). No differences were observed in either PF and PBT (CD3+) cell percentages among the examined groups of patients. A slight increase was noted in the percentage of CD4+ cells upon transition from the remission group to the groups with less favourable outcome of treatment. The increase was observed both in PB and in PF but only the latter showed statistically significant changes. On the contrary, percentage of T-cytotoxic/suppressor (CD8+) lymphocytes decreased upon transition from patients with the remission to those with stable disease and those with progression. These changes strongly affected the CD4/CD8 ratio. In PF, CD4/CD8 ratios were 2.13 +/- 0.9 and 4.18 +/- 1.6 in Group II and III, respectively (p < 0.01). In PB, the ratios were 1.88 +/- 1.1, 1.75 +/- 0.6, and 4.32 +/- 1.5 in Groups I, II and III respectively (Group I vs. Group III p < 0.01, Group II vs. Group III p < 0.01). During the study, five patients died due to ovarian cancer. In retrospective analysis, these patients showed progressive increase in CD4/CD8 ratio of PFT cells. Just before death, the ratio demonstrated an abrupt increase. In conclusion, the estimation of CD4+ and CD8+ cells as well as calculation of CD4/CD8 ratio for lymphocytes of peripheral blood and peritoneal fluid seems helpful in monitoring disease progression in ovarian cancer patients.
对27例卵巢癌患者进行了24个月的观察。患者分组如下：第一组——完全缓解（CR）或部分缓解（PR）；第二组——疾病稳定（SD）；第三组——疾病进展（PD）。对所有患者的腹腔积液（PF）和外周血（PB）中的T淋巴细胞表型进行了评估。在各检查患者组中，PF和PB中T（CD3+）细胞百分比均未观察到差异。从缓解组过渡到治疗效果较差的组时，CD4+细胞百分比略有增加。PB和PF中均观察到这种增加，但只有后者显示出统计学上的显著变化。相反，从缓解患者过渡到疾病稳定和疾病进展患者时，T细胞毒性/抑制（CD8+）淋巴细胞百分比降低。这些变化强烈影响CD4/CD8比值。在PF中，第二组和第三组的CD4/CD8比值分别为2.13±0.9和4.18±1.6（p<0.01）。在PB中，第一组、第二组和第三组的比值分别为1.88±1.1、1.75±0.6和4.32±1.5（第一组与第三组比较，p<0.01；第二组与第三组比较，p<0.01）。研究期间，5例患者死于卵巢癌。回顾性分析显示，这些患者PF T细胞的CD4/CD8比值逐渐升高。临死前，该比值急剧上升。总之，对外周血和腹腔积液淋巴细胞中CD4+和CD8+细胞的评估以及CD4/CD8比值的计算似乎有助于监测卵巢癌患者的疾病进展。
